Sunshine Biopharma (NASDAQ:SBFM) Shares Down 2.8% – Should You Sell?

Sunshine Biopharma, Inc. (NASDAQ:SBFM) shares fell 2.8% on Friday . The stock traded as low as $1.03 and last traded at $1.05. 28,132 shares changed hands during mid-day trading, a decline of 29% from the average session volume of 39,881 shares. The stock had previously closed at $1.0799.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Sunshine Biopharma in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.00.

Sunshine Biopharma Stock Down 2.8%

The business has a 50 day moving average price of $1.06 and a 200 day moving average price of $1.29. The stock has a market cap of $5.15 million, a P/E ratio of -0.71 and a beta of 1.37.

Sunshine Biopharma (NASDAQ:SBFM) last issued its quarterly earnings results on Friday, April 3rd. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.19). The business had revenue of $8.58 million for the quarter, compared to the consensus estimate of $10.00 million. Sunshine Biopharma had a negative return on equity of 27.14% and a negative net margin of 17.86%.

Institutional Trading of Sunshine Biopharma

A number of large investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in Sunshine Biopharma in the 4th quarter worth about $29,000. Two Sigma Investments LP purchased a new stake in Sunshine Biopharma in the 3rd quarter valued at about $32,000. Finally, Citadel Advisors LLC grew its stake in Sunshine Biopharma by 23.1% in the 3rd quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock worth $116,000 after acquiring an additional 14,656 shares in the last quarter. 41.98% of the stock is owned by hedge funds and other institutional investors.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.